Evolution of the Average Target: AstraZeneca PLC

Evolution of the Average Target - AstraZeneca PLC

Evolution of the Target Price: AstraZeneca PLC

Evolution of the Target Price - AstraZeneca PLC

Changes in Analyst Recommendations: AstraZeneca PLC

0e9669.Jf4xW79_vZjm7eK4XrLgsP5iJrKzOOdPWy7qFBOD0_c.FsZBN4kM--nThbTZPMe4ncc9dPj6SZcWdmqHbGTH_rNUyHZ20zbu4KuDsw~c19c051aa06b6e03de75eddf45265247
07/10 Berenberg Trims AstraZeneca PT, Affirms Outperform Rating MT
07/10 Deutsche Bank ups Glencore, BHP price targets AN
07/10 AstraZeneca PLC : Buy rating from Berenberg ZD
07/10 AstraZeneca PLC : Jefferies gives a Buy rating ZD
07/10 AstraZeneca PLC : Bernstein reaffirms its Buy rating ZD
06/10 Genmab in Good Health, Schneider Lacks Energy Zonebourse
06/10 BofA Forecasts 'In-line' Q3, Unchanged FY26 Outlook for AstraZeneca Amid Oncology Momentum MT
30/09 AstraZeneca PLC : Deutsche Bank reaffirms its Neutral rating ZD
30/09 AstraZeneca's $2 Billion Investment in Summit Therapeutics Seen as 'Win-Win,' UBS Says MT
29/09 Stocks Defy the Pressure Zonebourse
29/09 AstraZeneca PLC : Jefferies keeps its Buy rating ZD
29/09 AstraZeneca PLC : RBC reaffirms its Buy rating ZD
29/09 AstraZeneca PLC : JP Morgan maintains a Buy rating ZD
29/09 AstraZeneca PLC : Deutsche Bank is Neutral ZD
18/09 Berenberg and Deutsche say buy Bytes Technology AN
16/09 AstraZeneca PLC : Gets a Buy rating from UBS ZD
16/09 Oddo BHF cuts Safestore to neutral, cuts target AN
16/09 AstraZeneca PLC : Buy rating from Jefferies ZD
16/09 AstraZeneca PLC : JP Morgan keeps its Buy rating ZD
16/09 AlphaValue/Baader Europe Notes GSK's Plans to Address Upcoming Patent Cliff; Price Target Down MT
16/09 Guardant Health Could Benefit From AstraZeneca Trial Failure, UBS Says MT
15/09 Deutsche Bank Upgrades AstraZeneca to Hold, Lifts PT MT
15/09 Berenberg Trims Price Target on AstraZeneca to $203 From $214, Keeps Buy Rating MT
15/09 Berenberg Maintains AstraZeneca at Buy as Pipeline Success Offsets Recent Setbacks; Price Target Down MT
15/09 Berenberg likes GSK; Deutsche Bank lifts Astra AN

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+12.79%
+7.03%
+2.22%
+8.71%
+5.14%
+4.76%
+31.69%
-4.73%
+5.43%
Average +8.12%
Weighted average by Cap. +8.65%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
25
Last Close Price
158.77USD
Average target price
209.08USD
Spread / Average Target
+31.69%
High Price Target
262.96USD
Spread / Highest target
+65.63%
Low Price Target
154.83USD
Spread / Lowest Target
-2.48%

Analyst Consensus Detail

Analyst consensus - AstraZeneca PLC

Consensus revision (last 18 months)

Consensus revision (last 18 months) - AstraZeneca PLC
Trader
Investor
Global
Quality
ESG MSCI
A
Ratings Surperformance© - AstraZeneca PLC